- Cure on its Own Accelerated Timetable (COAT)
- Owning One's Healing
- Owning One's Cure
- Cares, Comforts and Cures
Sentia Medical Sciences, Inc. is an emerging Biopharmaceutical Company that is developing new therapies for treating diseases resulting from the body's inability to cope under the assault of stressors (episodic or chronic; real or perceived; current or anticipated; physical, psychological or both, and involving or not cognitive functions).
Because the perception of a stressor is individual, so are the variable responses and physiological consequences. Stressors, therefore contribute to the onset or worsening of a wide variety of pathological conditions. It is well documented that stress affects the central nervous, immune, gastrointestinal, reproductive, cardiovascular and skin systems.
Sentia's scientists hypothesize that acute and chronic high levels of Corticotropin Releasing Factor (CRF, The stress hormone) and consequently adrenocorticotropin (ACTH) and corticosteroids are responsible for numerous diseases and that temporal or prolonged neutralization of CRF's action will reinstate homeostasis that will allow the body to heal on its own accelerated timetable.
Sentia's Primary Targets are the Corticotropin Releasing Factor Receptors 1 and 2 that modulate stress responses of the central nervous, immune, gastrointestinal, reproductive, cardiovascular and skin systems.
Sentia’s Technology is based on the ability of its proprietary molecules to block the deleterious effects of stress (i.e. antagonize endogenous CRF).
Sentia's Platform relies on diverse chemical scaffolds, established spectroscopic, in silico methodologies, extensive biological testing and 40 years of the Founder's exemplar experience in the design of novel and optimized ligands (drugs) to the native Hypothalamic Hormone Receptors and selective N-type voltage-gated calcium channel blocker
Sentia's mission is to manage, treat, and cure stress-related diseases mediated by the corticotropin releasing factor (CRF, The Stress Hormone) receptors widely distributed in the skin, gastrointestinal, immune, cardiovascular, reproductive, central nervous, and other systems.
A diagnosis of IBS has been reported for 10 to 20% of adults in the United States, and symptoms of IBS are responsible for over 3 million yearly visits to physicians. Research suggests that IBS is one of the most common functional GI disorders. Over 70% of IBS sufferers are women. The aggregate cost of irritable bowel syndrome in the United States has been estimated at $1.7-$10 billion in direct medical costs, with an additional $20 billion in indirect costs. Combining costs associated with physician visits, outpatient visits, and prescription drugs, each IBS patient could incur up to $5,000 medical expenses per year.
Sentia is unique in that it offers the prospect of novel as well as actual drug candidates (peptide CRF antagonists) for the treatment of a well identified pathological condition. Irritable Bowel Syndrome (IBS - market size >$1 billion) is a functional bowel disorder of the gastrointestinal (GI) tract characterized by recurrent abdominal pain and discomfort accompanied by alterations in bowel function, diarrhea, constipation or a combination of both, typically over months or years. Experimental data on specific peptide CRF antagonists demonstrate proof of concept for the treatment of IBS in human. Administration of CRF antagonists have also led to dramatic observations of hair re-growth in CRF-overexpressing mice and opens the door to multiple clinical applications that involve the skin, gastrointestinal, immune, cardiovascular, reproductive, and central nervous systems.